8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps; Thomas Vanwolleghem; Marc van der Valk; Guido E. van den Berk; Marjo van Kasteren; Dirk Posthouwer; Anthonius S. M. Dofferhoff; Bart van Hoek; Dewkoemar Ramsoekh; Jelle Koopsen; Janke Schinkel; Eric Florence; Joop E. Arends; Bart J. Rijnders

doi:https://doi.org/10.1016/j.jhep.2018.10.032

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S. M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnders

Research output: Contribution to journal › Letter › Academic › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	554-557
Number of pages	4
Journal	Journal of Hepatology
Volume	70
Issue number	3
DOIs	https://doi.org/10.1016/j.jhep.2018.10.032
Publication status	Published - 1 Mar 2019

Access to Document

https://doi.org/10.1016/j.jhep.2018.10.032

Cite this

Boerekamps, A., Vanwolleghem, T., van der Valk, M., van den Berk, G. E., van Kasteren, M., Posthouwer, D., Dofferhoff, A. S. M., van Hoek, B., Ramsoekh, D., Koopsen, J., Schinkel, J., Florence, E., Arends, J. E., & Rijnders, B. J. (2019). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 70(3), 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

@article{a0a70b448e9e4d73a4b57ce6c50f01af,

title = "8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)",

author = "Anne Boerekamps and Thomas Vanwolleghem and {van der Valk}, Marc and {van den Berk}, {Guido E.} and {van Kasteren}, Marjo and Dirk Posthouwer and Dofferhoff, {Anthonius S. M.} and {van Hoek}, Bart and Dewkoemar Ramsoekh and Jelle Koopsen and Janke Schinkel and Eric Florence and Arends, {Joop E.} and Rijnders, {Bart J.}",

year = "2019",

month = mar,

day = "1",

doi = "https://doi.org/10.1016/j.jhep.2018.10.032",

language = "English",

volume = "70",

pages = "554--557",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "3",

}

Boerekamps, A, Vanwolleghem, T, van der Valk, M, van den Berk, GE, van Kasteren, M, Posthouwer, D, Dofferhoff, ASM, van Hoek, B, Ramsoekh, D , Koopsen, J , Schinkel, J, Florence, E, Arends, JE & Rijnders, BJ 2019, '8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)', Journal of Hepatology, vol. 70, no. 3, pp. 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

TY - JOUR

T1 - 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

AU - Boerekamps, Anne

AU - Vanwolleghem, Thomas

AU - van der Valk, Marc

AU - van den Berk, Guido E.

AU - van Kasteren, Marjo

AU - Posthouwer, Dirk

AU - Dofferhoff, Anthonius S. M.

AU - van Hoek, Bart

AU - Ramsoekh, Dewkoemar

AU - Koopsen, Jelle

AU - Schinkel, Janke

AU - Florence, Eric

AU - Arends, Joop E.

AU - Rijnders, Bart J.

PY - 2019/3/1

Y1 - 2019/3/1

UR - http://www.scopus.com/inward/record.url?scp=85060958739&partnerID=8YFLogxK

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060958739&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30527953

U2 - https://doi.org/10.1016/j.jhep.2018.10.032

DO - https://doi.org/10.1016/j.jhep.2018.10.032

M3 - Letter

C2 - 30527953

SN - 0168-8278

VL - 70

SP - 554

EP - 557

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 3

ER -

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Access to Document

Other files and links

Cite this